{"id":52657,"date":"2023-01-06T23:02:36","date_gmt":"2023-01-06T22:02:36","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/medx-announces-closing-of-secured-convertible-debenture-financing\/"},"modified":"2023-01-06T23:02:36","modified_gmt":"2023-01-06T22:02:36","slug":"medx-announces-closing-of-secured-convertible-debenture-financing","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/medx-announces-closing-of-secured-convertible-debenture-financing\/","title":{"rendered":"MedX Announces Closing of Secured Convertible Debenture Financing"},"content":{"rendered":"
\n

MISSISSAUGA, Ontario–(BUSINESS WIRE)–$MDX<\/a> #SkinCancer<\/a>–MedX Health Corp. (\u201cMedX<\/b>\u201d or the \u201cCompany<\/b>\u201d) (TSXV: MDX<\/b>), a global leader in teledermatology, is pleased to announce that, further to its Press Release dated November 18, 2022, it has closed a private placement financing to raise $1.5 million by issuance of a Secured Convertible Debenture (\u201cConvertible Debenture<\/b>\u201d).\n<\/p>\n

<\/a><\/p>\n

\nSecured Convertible Debenture<\/span><\/b>\n<\/p>\n

\nUnder the terms of the Convertible Debenture, funding of $1.5 million has been drawn down on the express basis that the funds advanced may be applied specifically and only<\/span> to expenses notified to and approved by the Lender. Interest is payable at 8% per year, payable Quarterly. The Convertible Debenture is secured by a fixed and floating charge over all assets and undertaking of the Borrower, has a Term expiring on December 31, 2027, and is subject to customary provisions in the event of default. The Convertible Debenture is convertible into units (\u201cUnit<\/b>(s<\/b>)\u201d) at the option of the Lender. Each Unit shall comprise one common share and one share purchase Warrant (\u201cWarrant<\/b>(s<\/b>)\u201d). The Conversion Price shall be $0.05 per Unit if the Conversion Right is exercised prior to November 18, 2023, which is the first anniversary of the original Price Reservation Date for this placement, and $0.10 per Unit thereafter for the remainder of the Term. The Exercise Price of Warrants is $0.20, and the expiration date of any Warrants issued shall be December 31, 2027. Any securities issued or issuable on Conversion or on exercise of Warrants will be subject to a four month hold period from the original issue date of the Convertible Debenture.\n<\/p>\n

\nRelated party transaction.<\/span><\/b>\n<\/p>\n

\nThe sole subscriber under the placement is Forest Lane Holdings Limited, a company controlled by David Hennigar, a director of the Company, and accordingly this is a \u201crelated party transaction\u201d as such term is defined by Multilateral Instrument 61-101 \u2013 Protection of Minority Security Holders in Special Transactions<\/i> (\u201cMI 61-101<\/b>\u201d). In order to comply with the Policies of the TSXV, the Convertible Debenture and the underlying Warrant comprised in the Units each contain provisions requiring disinterested shareholder approval, as envisaged by MI 61-101, prior to either Conversion of the Debenture or Exercise of any Warrants in the event that the share issuance on Conversion or Exercise, as the case may be, would take the shareholding of the Debenture holder of 20% or more of the then-issued and outstanding shares. In connection with the issuance of the Convertible Debenture, the Company relies on exemptions from formal valuation and minority shareholder approval requirements set out in MI 61-101 as (a) the fair market value of the proposed placement to Forest Lane Holdings Limited does not exceed 25% of the market capitalization of the Company and the conditions in section 5.7(1)(a) of MI 61-101 are met, (b) the fair market value of the securities being distributed is less than $2,500,000 and the conditions in section 5.7(1)(b) of MI 61-101 are met, and (c) the financial hardship provisions of section 5.7(1)(e) of MI 61-101 are met.\n<\/p>\n

\nAbout MedX Health Corp:<\/b>\n<\/p>\n

\nMedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy\u00ae<\/sup> on DermSecure\u00ae<\/sup> telemedicine platform, utilizing its SIAscopy\u00ae<\/sup> technology. SIAscopy\u00ae<\/sup> is also imbedded in its products SIAMETRICS\u00ae<\/sup>, SIMSYS\u00ae<\/sup>, and MoleMate\u00ae<\/sup>, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS\u00ae<\/sup>, SIMSYS\u00ae<\/sup>, and MoleMate\u00ae<\/sup> include hand-held devices that use patented technology utilizing light and its remittance to view suspicious moles and lesions up to 2mm beneath in a pain-free, non-invasive manner. Its patented software then creates real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformit\u00e9 Europ\u00e9enne for use in Canada, the U.S., Australia, New Zealand, the European Union, Brazil and Turkey.\n<\/p>\n

\nwww.medxhealth.com<\/a><\/b><\/span>.\n<\/p>\n

\nNeither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/i><\/b>\n<\/p>\n

\nThis Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.<\/i><\/b>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nBill Mitoulas, Investor Relations
\n
MedX Health Corp.
\n
bill@medxhealth.com<\/a>
+1-416-479-9547\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MISSISSAUGA, Ontario–(BUSINESS WIRE)–$MDX #SkinCancer–MedX Health Corp. (\u201cMedX\u201d or the \u201cCompany\u201d) (TSXV: MDX), a global leader in teledermatology, is pleased to announce that, further to its Press Release dated November 18, 2022, it has closed a private placement financing to raise $1.5 million by issuance of a Secured Convertible Debenture (\u201cConvertible Debenture\u201d). Secured Convertible Debenture Under … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52657","6":"format-standard","7":"category-industry"},"yoast_head":"\nMedX Announces Closing of Secured Convertible Debenture Financing - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/medx-announces-closing-of-secured-convertible-debenture-financing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedX Announces Closing of Secured Convertible Debenture Financing - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MISSISSAUGA, Ontario–(BUSINESS WIRE)–$MDX #SkinCancer–MedX Health Corp. (\u201cMedX\u201d or the \u201cCompany\u201d) (TSXV: MDX), a global leader in teledermatology, is pleased to announce that, further to its Press Release dated November 18, 2022, it has closed a private placement financing to raise $1.5 million by issuance of a Secured Convertible Debenture (\u201cConvertible Debenture\u201d). Secured Convertible Debenture Under ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/medx-announces-closing-of-secured-convertible-debenture-financing\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-06T22:02:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230106005444\/en\/1679642\/21\/MedX_Logo_copy.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-announces-closing-of-secured-convertible-debenture-financing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-announces-closing-of-secured-convertible-debenture-financing\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"MedX Announces Closing of Secured Convertible Debenture Financing\",\"datePublished\":\"2023-01-06T22:02:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-announces-closing-of-secured-convertible-debenture-financing\\\/\"},\"wordCount\":703,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-announces-closing-of-secured-convertible-debenture-financing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230106005444\\\/en\\\/1679642\\\/21\\\/MedX_Logo_copy.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-announces-closing-of-secured-convertible-debenture-financing\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-announces-closing-of-secured-convertible-debenture-financing\\\/\",\"name\":\"MedX Announces Closing of Secured Convertible Debenture Financing - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-announces-closing-of-secured-convertible-debenture-financing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-announces-closing-of-secured-convertible-debenture-financing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230106005444\\\/en\\\/1679642\\\/21\\\/MedX_Logo_copy.jpg\",\"datePublished\":\"2023-01-06T22:02:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-announces-closing-of-secured-convertible-debenture-financing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-announces-closing-of-secured-convertible-debenture-financing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-announces-closing-of-secured-convertible-debenture-financing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230106005444\\\/en\\\/1679642\\\/21\\\/MedX_Logo_copy.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230106005444\\\/en\\\/1679642\\\/21\\\/MedX_Logo_copy.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-announces-closing-of-secured-convertible-debenture-financing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MedX Announces Closing of Secured Convertible Debenture Financing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MedX Announces Closing of Secured Convertible Debenture Financing - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/medx-announces-closing-of-secured-convertible-debenture-financing\/","og_locale":"en_US","og_type":"article","og_title":"MedX Announces Closing of Secured Convertible Debenture Financing - Pharma Trend","og_description":"MISSISSAUGA, Ontario–(BUSINESS WIRE)–$MDX #SkinCancer–MedX Health Corp. (\u201cMedX\u201d or the \u201cCompany\u201d) (TSXV: MDX), a global leader in teledermatology, is pleased to announce that, further to its Press Release dated November 18, 2022, it has closed a private placement financing to raise $1.5 million by issuance of a Secured Convertible Debenture (\u201cConvertible Debenture\u201d). Secured Convertible Debenture Under ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/medx-announces-closing-of-secured-convertible-debenture-financing\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-06T22:02:36+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230106005444\/en\/1679642\/21\/MedX_Logo_copy.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/medx-announces-closing-of-secured-convertible-debenture-financing\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/medx-announces-closing-of-secured-convertible-debenture-financing\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"MedX Announces Closing of Secured Convertible Debenture Financing","datePublished":"2023-01-06T22:02:36+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/medx-announces-closing-of-secured-convertible-debenture-financing\/"},"wordCount":703,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/medx-announces-closing-of-secured-convertible-debenture-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230106005444\/en\/1679642\/21\/MedX_Logo_copy.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/medx-announces-closing-of-secured-convertible-debenture-financing\/","url":"https:\/\/pharma-trend.com\/en\/medx-announces-closing-of-secured-convertible-debenture-financing\/","name":"MedX Announces Closing of Secured Convertible Debenture Financing - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/medx-announces-closing-of-secured-convertible-debenture-financing\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/medx-announces-closing-of-secured-convertible-debenture-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230106005444\/en\/1679642\/21\/MedX_Logo_copy.jpg","datePublished":"2023-01-06T22:02:36+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/medx-announces-closing-of-secured-convertible-debenture-financing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/medx-announces-closing-of-secured-convertible-debenture-financing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/medx-announces-closing-of-secured-convertible-debenture-financing\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230106005444\/en\/1679642\/21\/MedX_Logo_copy.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230106005444\/en\/1679642\/21\/MedX_Logo_copy.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/medx-announces-closing-of-secured-convertible-debenture-financing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"MedX Announces Closing of Secured Convertible Debenture Financing"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52657","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52657"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52657\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52657"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52657"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52657"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}